279 related articles for article (PubMed ID: 33835640)
21. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis.
Colosimo S; Ravaioli F; Petroni ML; Brodosi L; Marchignoli F; Barbanti FA; Sasdelli AS; Marchesini G; Pironi L
Liver Int; 2021 Apr; 41(4):731-742. PubMed ID: 33497019
[TBL] [Abstract][Full Text] [Related]
22. Acute effect of add-on therapy with tofogliflozin, a sodium glucose co-transporter 2 inhibitor, on 24-hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitors.
Iijima T; Hosonuma S; Kurai H; Kajitani H; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
Int J Clin Pract; 2021 Nov; 75(11):e14732. PubMed ID: 34388297
[TBL] [Abstract][Full Text] [Related]
23. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
24. Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients With Type 2 Diabetes and the Incidence of Retinal Vein Occlusion in Taiwan.
Tsai HR; Lin YJ; Yeh JI; Lin SM; Liu PP; Chang YC; Lee YC; Loh CH; Huang HK
Invest Ophthalmol Vis Sci; 2024 Jun; 65(6):19. PubMed ID: 38864813
[TBL] [Abstract][Full Text] [Related]
25. The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.
Pan X; Xu S; Li J; Tong N
Front Endocrinol (Lausanne); 2020; 11():599355. PubMed ID: 33335511
[TBL] [Abstract][Full Text] [Related]
26. Prescription Trends for the Antidiabetic Agents Used to Treat Type 2 Diabetes Mellitus in Japan from 2012-2020: a Time-Series Analysis.
Iketani R; Imai S
Biol Pharm Bull; 2023; 46(4):592-598. PubMed ID: 37005303
[TBL] [Abstract][Full Text] [Related]
27. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
Wilkinson S; Williamson E; Pokrajac A; Fogarty D; Stirnadel-Farrant H; Smeeth L; Douglas IJ; Tomlinson LA
Diabetes Obes Metab; 2020 May; 22(5):847-856. PubMed ID: 31957254
[TBL] [Abstract][Full Text] [Related]
28. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
29. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized.
Wood SJ; Bell JS; Magliano DJ; Shaw JE; Cesari M; Ilomaki J
Front Pharmacol; 2022; 13():886834. PubMed ID: 35903329
[No Abstract] [Full Text] [Related]
31. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
Han SJ; Ha KH; Lee N; Kim DJ
Diabetes Obes Metab; 2021 Mar; 23(3):682-691. PubMed ID: 33236515
[TBL] [Abstract][Full Text] [Related]
33. Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea).
Koh ES; Han K; Nam YS; Wittbrodt ET; Fenici P; Kosiborod MN; Heerspink HJL; Yoo SJ; Kwon HS
Diabetes Obes Metab; 2021 Feb; 23(2):455-466. PubMed ID: 33118320
[TBL] [Abstract][Full Text] [Related]
34. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.
Mishriky BM; Powell JR; Wittwer JA; Chu JX; Sewell KA; Wu Q; Cummings DM
Diabetes Obes Metab; 2019 Oct; 21(10):2274-2283. PubMed ID: 31168889
[TBL] [Abstract][Full Text] [Related]
35. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
Paul SK; Bhatt DL; Montvida O
Eur Heart J; 2021 May; 42(18):1728-1738. PubMed ID: 33289789
[TBL] [Abstract][Full Text] [Related]
36. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
[TBL] [Abstract][Full Text] [Related]
37. Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes.
Foresta A; Ojeda-Fernandez L; Macaluso G; Roncaglioni MC; Tettamanti M; Fortino I; Leoni O; Genovese S; Baviera M
Clin Ther; 2023 Apr; 45(4):e115-e126. PubMed ID: 36933975
[TBL] [Abstract][Full Text] [Related]
38. Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020-Nationwide Data from a Register-Based Analysis.
Jermendy G; Kiss Z; Rokszin G; Abonyi-Tóth Z; Lengyel C; Kempler P; Wittmann I
Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295543
[TBL] [Abstract][Full Text] [Related]
39. Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases.
Qiu M; Zhou X; Zhang M
Diabetes Obes Metab; 2022 Mar; 24(3):575-577. PubMed ID: 34729884
[No Abstract] [Full Text] [Related]
40. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.
Zhuo M; Hawley CE; Paik JM; Bessette LG; Wexler DJ; Kim DH; Tong AY; Kim SC; Patorno E
JAMA Netw Open; 2021 Oct; 4(10):e2130762. PubMed ID: 34705014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
